⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Rapamycin and mTOR Inhibition
Current understanding
The most robust animal-lifespan drug result; human dosing trials (e.g. intermittent low-dose) are early.
Evidence log
- 2026-11-11 — Late Life Asparagine Endopeptidase Inhibition Extends Lifespan in Mice: cross-connection with asparagine-endopeptidase-inhibitors: [animal-model] The report places AEP inhibition alongside rapamycin as a late-start mouse lifespan intervention; this is a comparison of intervention timing, not head-to-head evidence or evidence of equivalent efficacy. (novelty: 4)
- 2026-11-01 — Klotho Deficiency Impairs Distal Potassium Homeostasis Through mTORC1-Dependent Suppression of ROMK.: [animal-model] A mouse study found that rapamycin or Klotho supplementation reversed impaired distal renal potassium handling associated with Klotho deficiency and mTORC1-dependent ROMK suppression, adding a renal-function result without establishing human electrolyte benefits or lifespan extension. [animal-model] (novelty: 3)
- 2026-11-05 — Rapamycin and human longevity among kidney transplant recipients surviving the first year.: [human-observational] A propensity-score-weighted cohort of over 11,000 kidney transplant recipients who survived the first post-transplant year, followed for a median of 11 years, found no association between chronic rapamycin exposure and improved long-term survival—a null human survival finding that contrasts with animal lifespan results but cannot establish causality or resolve effects in healthy people using intermittent low-dose regimens. [human-observational] (novelty: 4)
- 2026-11-01 — Constitutive Activation of Skeletal Muscle mTORC1 Drives Pro-Inflammatory Gene Expression in Skeletal Muscle of Aged Mice.: [animal-model] In 27-month-old mice, muscle-specific Depdc5 knockout causing constitutive mTORC1 activation increased skeletal-muscle pro-inflammatory gene expression and TNF-α levels; dietary rapamycin only partially rescued the reported phenotype without suppressing the induced inflammatory markers, contrasting with anti-inflammatory findings in aged atherosclerotic mice and showing that those effects do not generalize across these models. [animal-model] (novelty: 3)
- 2026-10-09 — Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus).: Narrative review argues oral rapamycin reaches brain parenchyma and inhibits CNS mTORC1 functionally despite unreliable CSF detection, recommending ADRD trials use pharmacodynamic surrogates rather than CSF levels as a brain-penetration proxy — synthesis of prior human tissue and preclinical data, no new primary outcomes. [expert-opinion] (novelty: 3)
- 2026-10-06 — Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions.: Cross-sectional canine (laboratory Beagle) immune-aging study with short-term 90-day geroprotector arms reports rapamycin produced the broadest exploratory cytokine response versus canagliflozin or dietary restriction, with sex-stratified immune patterns across the lifespan — small exploratory dog data, not an outcome trial. [animal-model] (novelty: 3)
- 2026-10-05 — Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.: Senotherapeutics systematic review groups rapamycin among senomorphic/anti-aging agents entering human trials and notes that completed human evidence across the class remains insufficient to establish clinical efficacy or long-term safety — contextual framing, no rapamycin-specific primary data. [expert-opinion] (novelty: 3)
- 2026-10-01 — Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.: Aged atherosclerotic mouse study with scRNA-seq: rapamycin reduced plaque macrophage content, shifted systemic/vascular T cells toward regulatory phenotypes, suppressed effector T/B responses, and lowered senescent leukocyte signatures — extends rapamycin’s animal profile into vascular immunoaging, no human CVD outcomes. [animal-model] (novelty: 3)
- 2026-08-01 — Senescent cardiac cells promote thrombus formation and impair fibrinolysis.: In vitro human cardiac fibroblast/endothelial cell study: rapamycin attenuated the pro-thrombotic phenotype (increased thrombin generation, impaired fibrinolysis) of doxorubicin-induced senescent cells — mechanistic extension of rapamycin’s senostatic profile into coagulation biology, no in vivo or human thrombosis outcomes. [mechanism-plausible] (novelty: 3)
- 2026-05-28 — Feedback loops between DNMT1 and autophagy as well as senescence promotes organ aging and canities.: Mouse DNMT1 study implicates autophagy suppression as part of the DNMT1→senescence feedback loop driving organ aging, offering a mechanistic adjacency for autophagy-restoring interventions like mTOR inhibition — no rapamycin arm tested, connection is inferential. [mechanism-plausible] (novelty: 3)
- 2026-09-16 — A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE): NIBBLE trial launch: 8-week placebo-controlled RCT in middle-aged APOE ε4 carriers testing daily 1 mg rapamycin (vs fasting-mimicking diet vs placebo) for safety, feasibility, and preliminary Alzheimer’s-risk biomarkers — protocol registration, not a readout. [expert-opinion] (novelty: 3)
- 2026-09-23 — Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice: Aged atherosclerotic mouse study reports rapamycin therapeutically reprograms immune responses to attenuate plaque inflammation and lymphoid immune activation — extends rapamycin’s animal profile into vascular immunoaging but no human atherosclerosis outcomes. [animal-model] (novelty: 3)
- 2026-09-23 — Lsp2 links mTORC1 to TOP mRNA translation and lifespan in Drosophila.: Drosophila genetic study identifies Lsp2 as a nutrient-induced adipose effector that amplifies mTORC1-driven 4E-BP-dependent TOP mRNA translation; Lsp2 loss extends fly lifespan through a route mechanistically distinct from rapamycin, adding a new upstream node in the mTOR–longevity axis. [animal-model] (novelty: 4)
- 2026-09-18 — Imeglimin provides dual hepatic and skeletal muscle protection in experimental MASH-associated sarcopenia.: cross-connection with imeglimin: Imeglimin’s anabolic effect ran through AKT–mTOR activation in muscle — opposite directionality to mTOR-inhibition longevity strategies, worth surfacing as a tissue-context contradiction. (novelty: 3)
- 2026-09-10 — EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.: Pilot single-arm human trial (1 mg/day × 4 weeks) in healthy middle-aged APOE4 carriers reports >15% increase in cerebral blood flow across multiple brain regions plus shifts in metabolic, inflammatory, and microbiome profiles, with little CBF effect in non-carriers — earliest genotype-stratified human cerebrovascular signal for low-dose rapamycin, but uncontrolled and short-term. [human-rct] (novelty: 3)
- 2026-08-27 — A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation: Listed as one of two pharmacologic arms (alternative to lamivudine) in a feasibility trial combining exercise + spermidine + drug on systemic inflammation — registers as combination-stack framing, no new outcome data. [expert-opinion] (novelty: 3)
- 2026-06-25 — The Role of Sirolimus in Preventing Functional Decline in Older Adults: Proposed randomized controlled trial in older adults to test whether sirolimus reduces biomarkers of aging and slows functional decline and chronic-disease incidence — a protocol/proposal, not a readout, so it registers as intent-to-translate rather than new outcome data. [expert-opinion] [expert-opinion] (novelty: 3)
- 2026-09-07 — Mice With Growth Hormone Halted in Middle Age Live Longer: cross-connection with growth-hormone-receptor-inhibition: GHR signaling converges on IGF-1/mTOR; midlife-initiated GHR shutdown extending lifespan parallels rapamycin’s late-onset efficacy on the same nutrient-sensing axis. (novelty: 3)
- 2026-09-08 — Late-Life GLP-1 Treatment Increases Lifespan in Female Mice: cross-connection with glp1-agonists: Late-life semaglutide joins rapamycin as one of the few compounds showing median lifespan extension when initiated in aged mice, inviting direct comparison of geroprotector potency and sex-specificity. (novelty: 4)
- 2026-07-29 — Complosome as a key modulator of cellular senescence, aging and age-related diseases.: cross-connection with complement-inhibitors: Complosome signaling converges on mTOR, suggesting intracellular complement modulation and mTOR inhibition may act on overlapping senescence/inflammaging circuitry. (novelty: 3)
- 2026-08-26 — Rapamycin attenuates age-related atrial remodeling and fibrillation by targeting HIF-1α-mediated metabolic dysregulation.: D-galactose-accelerated aging mouse study reports rapamycin reduces atrial fibrillation susceptibility and atrial electrical/structural remodeling via inhibition of HIF-1α-driven metabolic dysregulation, with authors noting partly mTOR-independent effects — extends rapamycin’s animal anti-aging profile into cardiac electrophysiology but no human AF data. [animal-model] (novelty: 3)
- 2026-06-29 — Mammalian aging involves genome-wide splicing degeneration leading to functional decline.: Multi-tissue mammalian aging analysis reports genome-wide RNA splicing degeneration (loss of splicing fidelity affecting reading frames and protein domains) that rises with chronological age and is attenuated by calorie restriction or rapamycin — extends mTOR-inhibition’s molecular footprint to splicing quality control, though evidence is observational/associative rather than an outcome trial. [animal-model] (novelty: 3)
- 2026-07-17 — Constitutive mTORC1 activation in skeletal muscle increases inflammation but is not sufficient to impair glucose tolerance.: 2026 mouse study (adult-onset muscle-specific Depdc5/GATOR1 deletion) shows constitutive skeletal-muscle mTORC1 activation drives inflammatory/immune transcriptional remodeling but is insufficient to impair systemic glucose tolerance even on a Western diet — dissociating muscle mTORC1 hyperactivation from the assumed insulin-resistance link. [animal-model] (novelty: 3)
- 2026-08-01 — A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.: Systems-pharmacology model predicts rapamycin (rather than metformin) as the third component of the aging-optimal triple with GLP-1 RA + SGLT2i, consistent with its stronger animal-lifespan signal but derived from in silico calibration — no new human data. [mechanism-plausible] (novelty: 3)
- 2026-08-11 — Pentadecanoic acid as a potential endogenous mTOR modulator for age-related female infertility: Mechanistic insights, molecular docking evidence, and therapeutic perspectives.: 2026-08 — Review contrasts rapamycin’s fertility-limiting effects with a proposed milder endogenous mTOR modulator (pentadecanoic acid) for ovarian aging; reinforces the reproductive-toxicity caveat of mTOR inhibition rather than adding new rapamycin outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-01 — An ANGPTL8-AKT2-mTOR Axis Drives Adipose Senescence and Aging-Related Functional Decline.: Mechanistic cross-link: ANGPTL8 identified as an upstream endocrine activator of AKT2-mTOR-S6K signaling in adipose tissue, with Angptl8 deletion phenocopying aspects of mTOR suppression in mice (mechanism-plausible connection to a new upstream node). [mechanism-plausible] (novelty: 4)
Open questions
Related
Contributing findings
Rapamycin and human longevity among kidney transplant recipients surviving the first year.
05-nov-2026
novelty 4
per-area 4
strengthens
Age: a modifiable risk factor for cardiovascular disease?
02-nov-2026
novelty 2
per-area 1
mentions
Klotho Deficiency Impairs Distal Potassium Homeostasis Through mTORC1-Dependent Suppression of ROMK.
01-nov-2026
novelty 3
per-area 3
strengthens
Constitutive Activation of Skeletal Muscle mTORC1 Drives Pro-Inflammatory Gene Expression in Skeletal Muscle of Aged Mice.
01-nov-2026
novelty 3
per-area 3
strengthens
Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus).
09-oct-2026
novelty 3
per-area 3
strengthens
Is there a role for senotherapeutics in the treatment of giant cell arteritis?
07-oct-2026
novelty 2
per-area 2
mentions
Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions.
06-oct-2026
novelty 3
per-area 3
strengthens
Therapeutic reversal of cellular senescence: A systematic review of senolytics, senomorphics and anti-ageing therapies in human clinical trials.
05-oct-2026
novelty 3
per-area 3
strengthens
Caloric restriction mimetics rewire the AMPK-mTOR-ULK1 signaling nexus to restore autophagic proteostasis in the aging brain.
05-oct-2026
novelty 2
per-area 2
strengthens
Fight Aging! Newsletter, October 5th 2026
04-oct-2026
novelty 2
per-area 2
mentions
Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.
01-oct-2026
novelty 3
per-area 3
strengthens
Berberine as a multi-hallmark modulator of aging: From AMPK and mitophagy to inflammaging and the SASP.
28-sep-2026
novelty 2
per-area 2
mentions
Rapamycin across biology and medicine: From molecular mechanisms to clinical and translational frontiers.
24-sep-2026
novelty 2
per-area 2
strengthens
Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice
23-sep-2026
novelty 3
per-area 3
strengthens
Lsp2 links mTORC1 to TOP mRNA translation and lifespan in Drosophila.
23-sep-2026
novelty 4
per-area 4
strengthens
Tissue-specific aging clocks map structured aging-modulatory drug-score patterns across 49 human tissue and cell-line categories.
22-sep-2026
novelty 3
per-area 2
mentions
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
strengthens
mTOR signaling in aging: from causality to geroprotective interventions and hallmark-level outcomes.
19-sep-2026
novelty 2
per-area 2
strengthens
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
16-sep-2026
novelty 3
per-area 3
strengthens
EXPRESS: Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.
10-sep-2026
novelty 3
per-area 3
strengthens
Immunosenescence, inflammaging, and metabolic disease: A geroscience perspective on mechanisms and links.
10-sep-2026
novelty 2
per-area 2
mentions
Copper and iron engage distinct metabolic programs for cellular survival.
09-sep-2026
novelty 3
per-area 2
mentions
The Challenge of Cheap Interventions and Expensive Clinical Trials
07-sep-2026
novelty 2
per-area 2
mentions
LivAge: An Online Aging Clock for Murine Transcriptomic Age Estimation.
01-sep-2026
novelty 3
per-area 2
strengthens
A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.
01-sep-2026
novelty 2
per-area 2
mentions
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
27-aug-2026
novelty 3
per-area 3
strengthens
Rapamycin attenuates age-related atrial remodeling and fibrillation by targeting HIF-1α-mediated metabolic dysregulation.
26-aug-2026
novelty 3
per-area 3
strengthens
Thymus regeneration in countering immunosenescence: Mechanisms, strategies and future perspectives.
13-aug-2026
novelty 2
per-area 2
strengthens
High-fructose diet-induced gut dysbiosis as a mechanistic driver of chronic inflammation and accelerated biological aging: a comprehensive review.
13-aug-2026
novelty 2
per-area 2
mentions
Review: The African turquoise killifish as a model for the integrative physiology of vertebrate aging.
11-aug-2026
novelty 2
per-area 2
mentions
Pentadecanoic acid as a potential endogenous mTOR modulator for age-related female infertility: Mechanistic insights, molecular docking evidence, and therapeutic perspectives.
11-aug-2026
novelty 3
per-area 3
strengthens
Senescent cardiac cells promote thrombus formation and impair fibrinolysis.
01-aug-2026
novelty 3
per-area 3
strengthens
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
01-aug-2026
novelty 3
per-area 3
strengthens
An ANGPTL8-AKT2-mTOR Axis Drives Adipose Senescence and Aging-Related Functional Decline.
01-aug-2026
novelty 4
per-area 4
strengthens
Aging-related metabolic dysregulation in osteoporosis: mechanisms and therapeutic strategies.
27-jul-2026
novelty 2
per-area 2
mentions
Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing.
24-jul-2026
novelty 2
per-area 2
mentions
Chasing the FoxO in Metabolic Disorders: Novel Considerations for Oxidative Stress, Programmed Cell Death, Wnt, and the Gut Microbiome.
20-jul-2026
novelty 2
per-area 2
mentions
Constitutive mTORC1 activation in skeletal muscle increases inflammation but is not sufficient to impair glucose tolerance.
17-jul-2026
novelty 3
per-area 3
strengthens
Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
16-jul-2026
novelty 2
per-area 1
mentions
Biological limits of lifespan extension: Evidence for a shift from pathway leverage to system-level buffering across species.
12-jul-2026
novelty 3
per-area 2
weakens
Effects of nutritional interventions on biomarkers of cellular senescence in humans: A systematic review.
04-jul-2026
novelty 3
per-area 2
strengthens
Mammalian aging involves genome-wide splicing degeneration leading to functional decline.
29-jun-2026
novelty 3
per-area 3
strengthens
From lifespan extension to hallmark-informed gerotherapeutic prioritization: A bibliometric-guided, strategy-oriented review of anti-aging drug research.
28-jun-2026
novelty 3
per-area 2
strengthens
Orchestration of Autophagy and Senescence: Kinases Take the Center Stage.
28-jun-2026
novelty 2
per-area 2
mentions
The Role of Sirolimus in Preventing Functional Decline in Older Adults
25-jun-2026
novelty 3
per-area 3
strengthens
MTOR Inhibitors in Older Adults
25-jun-2026
novelty 2
per-area 2
strengthens
Biomarkers and therapies associated with Hutchinson-Gilford Progeria Syndrome.
17-jun-2026
novelty 2
per-area 2
mentions
Autophagy decline during ageing: Molecular regulation, tissue specificity, and therapeutic potential.
30-may-2026
novelty 2
per-area 2
strengthens
Feedback loops between DNMT1 and autophagy as well as senescence promotes organ aging and canities.
28-may-2026
novelty 3
per-area 3
strengthens
Discrimination of normal from slow-aging mice by plasma metabolomic and proteomic features.
15-dec-2025
novelty 3
per-area 2
mentions